Where does GlaxoSmithKline Intellectual Property Development Limited rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), GlaxoSmithKline Intellectual Property Development Limited ranks #1,874 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

Is GlaxoSmithKline Intellectual Property Development Limited's patent grant rate increasing or decreasing?

GlaxoSmithKline Intellectual Property Development Limited's recent grant velocity is +7% compared to the prior five-year period (grant years, not application filing dates). The company is maintaining or growing its granted-patent output.

What does claim depth mean for GlaxoSmithKline Intellectual Property Development Limited's patents?

GlaxoSmithKline Intellectual Property Development Limited's patents average 15.9 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

GlaxoSmithKline Intellectual Property Development Limited

Q: How many patents does GlaxoSmithKline Intellectual Property Development Limited hold?

GlaxoSmithKline Intellectual Property Development Limited holds 214 US utility patents granted between 2015 and 2025, spanning 37 technology areas.

Q: What is GlaxoSmithKline Intellectual Property Development Limited's Innovation Score?

GlaxoSmithKline Intellectual Property Development Limited has an Innovation Score of 52.7 out of 100 (top 10% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Q: How is the GlaxoSmithKline Intellectual Property Development Limited patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO PatentsView assignee record - 214 granted patents across 37 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Glaxosmithkline ranks #1,874 of 49,997 tracked US assignees by granted-patent volume, with 214 patents across 37 technology areas.

#1,874
of 49,997 US assignees by volume: Top 10%
by Innovation Score (52.7/100): 15.9
avg claims per patent: +7%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R1874 · Foreign Corporation #1,874 · 214 grants

GRANTS-MID · TOP-DECILE · PHOTO-FINISH · CPC-FOCUS · INNOV-PAR · CLAIMS-RICH · TYPE-FRNCORP · VEL-FLAT · BOOK-FULL

GRANTS-MID 214 grants
TOP-DECILE #1,874/49,997
PHOTO-FINISH AWI Licensing
CPC-FOCUS A61P · 37 areas
INNOV-PAR 52.7/100
CLAIMS-RICH 15.9 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-FLAT +7% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: AWI Licensing LLC (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Glaxosmithkline’s 52.7 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 18.6 pts (35%) Velocity 3.1 pts (6%) Breadth 21.5 pts (41%) Claim depth 9.6 pts (18%)

Qualcomm Incorporated · highest

85
Construction… · near

53
GlaxoSmithKline… · this assignee

53
Paper Converting… · near

53
SAE Magnetics (H K ) · near

53
The Schepens Eye… · near

53
3D Lighting… · lowest

7

What this shows Glaxosmithkline's Innovation Score is 52.7/100 (top 10% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Glaxosmithkline?

Each dot is one of Glaxosmithkline’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Glaxosmithkline’s own 15.9 claims/patent is at or below the 16.4 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Glaxosmithkline vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Glaxosmithkline's grants concentrate

GlaxoSmithKline Intellectual Property Development Limited is a focused PatentsView assignee: 37 CPC subclasses with 84.1% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2019 (37 grants) versus a trough of 5 in 2016. By volume, Glaxosmithkline sits between Zoetis Services LLC and Minebea Co., Ltd..

Glaxosmithkline's three-year grant acceleration

From 2019–2021 to 2022–2024, GlaxoSmithKline Intellectual Property Development Limited moved from 97 to 45 grants (0.46x the prior three-year total, a multiple, not a CAGR). Among 3,296 tracked assignees with ≥100 grants and ≥20 prior-period grants, that multiple ranks #2,773. See the growth leaderboard.

Zoetis Services

215
AWI Licensing

214
Darfon

214
F5 Networks

214
Grundfos Holding…

214
Johnson Electric…

214
MKS Instruments

214
Minebea

214
Glaxosmithkline I… ◀

214

What this shows GlaxoSmithKline holds 214 patents at rank #1,874, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near GlaxoSmithKline

By rank, the assignees closest to #1,874 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in GlaxoSmithKline's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for GlaxoSmithKline, neither rank-band nor same-CPC leaders (those blocks stay above). In A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…), GlaxoSmithKline ranks #76 of 6,058 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (53 here).

SAE Magnetics (H.K.) Ltd. 53 The Schepens Eye Research Institute, Inc. 53 Construction Research & Technology GMBH 53 Paper Converting Machine Company 53

Similar claim depth

Nearest assignees by average claims per patent (15.9 here).

Wayne State University 15.9 avg Feitian Technologies Co., Ltd. 15.9 avg Electrolux Appliances Aktiebolag 15.9 avg Krones AG 15.9 avg

Glaxosmithkline's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

53 Top 10% higher than 90% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

GlaxoSmithKline Intellectual Property Development Limited patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	7	3.3%
2016	5	2.3%
2017	21	9.8%
2018	28	13.1%
2019	37	17.3%
2020	31	14.5%
2021	29	13.6%
2022	20	9.3%
2023	14	6.5%
2024	11	5.1%
2025partial year	11	5.1%

Which technologies does GlaxoSmithKline Intellectual Property Development Limited patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 180

C07D - Heterocyclic Compounds 151

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 112

C07K - Peptides 37

C07F - Acyclic, Carbocyclic OR Heterocyclic Compounds Containing Elements Other Than Carbon, Hydrogen, Halogen, Oxygen, Nitrogen, Sulfur, Selenium OR Tellurium 20

Y02A - Technologies FOR Adaptation TO Climate Change 15

C07H - SUGARS; Derivatives THEREOF; NUCLEOSIDES; NUCLEOTIDES; Nucleic Acids 12

C07B - General Methods OF Organic CHEMISTRY; Apparatus Therefor 12

C07C - Acyclic OR Carbocyclic Compounds 11

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 10

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 8

C12Y - Enzymes 5

C12Q - Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Microbiological OR Enzymological Processes 3

C12P - Fermentation OR Enzyme-using Processes TO Synthesise A Desired Chemical Compound OR Composition OR TO Separate Optical Isomers From A Racemic Mixture 3

B01L - Chemical OR Physical Laboratory Apparatus FOR General USE 2

Top 15 of 37 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

GlaxoSmithKline Intellectual Property Development Limited's patent record in context - here's where to go next.

GlaxoSmithKline Intellectual Property Development Limited's lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 84.1% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #1,874 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare GlaxoSmithKline Intellectual Property Development Limited against Zoetis Services LLC, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 52.7/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent , US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.